Bartlett JS - Search Results

1

Modification and labeling of AAV vector particles.

Büning H, Bolyard CM, Hallek M, Bartlett JS. Büning H, et al. Among authors: bartlett js. Methods Mol Biol. 2011;807:273-300. doi: 10.1007/978-1-61779-370-7_12. Methods Mol Biol. 2011. PMID: 22034035

2

Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes.

Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Arnold GS, et al. Among authors: bartlett js. Mol Ther. 2006 Jul;14(1):97-106. doi: 10.1016/j.ymthe.2006.02.014. Epub 2006 Apr 19. Mol Ther. 2006. PMID: 16624620 Free article.

3

Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.

Stachler MD, Chen I, Ting AY, Bartlett JS. Stachler MD, et al. Among authors: bartlett js. Mol Ther. 2008 Aug;16(8):1467-73. doi: 10.1038/mt.2008.129. Epub 2008 Jun 17. Mol Ther. 2008. PMID: 18560418 Free article.

4

Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery.

Davis AS, Federici T, Ray WC, Boulis NM, OʼConnor D, Clark KR, Bartlett JS. Davis AS, et al. Among authors: bartlett js. Neurosurgery. 2015 Feb;76(2):216-25; discussion 225. doi: 10.1227/NEU.0000000000000589. Neurosurgery. 2015. PMID: 25549186

5

RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.

Shi W, Bartlett JS. Shi W, et al. Among authors: bartlett js. Mol Ther. 2003 Apr;7(4):515-25. doi: 10.1016/s1525-0016(03)00042-x. Mol Ther. 2003. PMID: 12727115 Free article.

6

Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism.

Shi X, Fang G, Shi W, Bartlett JS. Shi X, et al. Among authors: bartlett js. Hum Gene Ther. 2006 Mar;17(3):353-61. doi: 10.1089/hum.2006.17.353. Hum Gene Ther. 2006. PMID: 16544984

7

Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody.

Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Bartlett JS, et al. Nat Biotechnol. 1999 Feb;17(2):181-6. doi: 10.1038/6185. Nat Biotechnol. 1999. PMID: 10052356

8

Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells.

Stachler MD, Bartlett JS. Stachler MD, et al. Among authors: bartlett js. Gene Ther. 2006 Jun;13(11):926-31. doi: 10.1038/sj.gt.3302738. Gene Ther. 2006. PMID: 16482202

9

Molecular characterization of adeno-associated viruses infecting children.

Chen CL, Jensen RL, Schnepp BC, Connell MJ, Shell R, Sferra TJ, Bartlett JS, Clark KR, Johnson PR. Chen CL, et al. Among authors: bartlett js. J Virol. 2005 Dec;79(23):14781-92. doi: 10.1128/JVI.79.23.14781-14792.2005. J Virol. 2005. PMID: 16282478 Free PMC article.

10

Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma.

Shi W, Hemminki A, Bartlett JS. Shi W, et al. Among authors: bartlett js. Gynecol Oncol. 2006 Dec;103(3):1054-62. doi: 10.1016/j.ygyno.2006.06.020. Epub 2006 Jul 25. Gynecol Oncol. 2006. PMID: 16870238

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page